65,437 trials
Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital Discharge — -2.1; 1.4 units…
Oncology
Primary: Absolute Oral Bioavailability — 69.75 Percentage
Spinal Cord Injury
Primary: 16-Item Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16) — 2; 0 participants — p=0.445
Type 2 Diabetes Mellitus
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.47; -0.83 percentage of hemoglobin — p=0.0004
Smoking
Primary: Point Prevalence Smoking Outcome at 12 Weeks (End of Treatment) — 24; 7 participants — p=<0.001
Breast Cancer
Primary: Progression Free Survival (Independent Assessment) — 9.0; 11.1 months — p=0.0731
Glaucoma
Primary: Assessment of Ocular Adverse Events — 0; 0; 0 Number of Reported Adverse Events
Acute Respiratory Distress Syndrome
Primary: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days — 20; 17 participants — p=0.53
Restless Legs Syndrome · Ekbom Syndrome · Willis-Ekbom Disease
Primary: Proportion of Patients Completing the Switch and Their Adverse Events — 17; 14; 3 participants
Cumulative Irritation
Primary: Number of Subjects That Showed no Significant Irritation — 0 participants
Rheumatoid Arthritis
Primary: Number of Participants With at Least One Serious Adverse Event (SAE) — 4; 19 participants
Vitreomacular Traction · Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Traction (VMT/VMA) at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain…
Kidney Stones · Ureteral Stones
Primary: Stone Passage — 18; 21 participants
Diabetes
Primary: To Assess the Change in HbA1c During the 6 Months Follow-up. — 2.1 percent
Moderate, Deep Sedation
Primary: Sedation Efficacy — 5.5; 6; 6 units on a scale — p=0.2